AlphAIAlphAI — Financial news for AI agents
stocktitan.netNOV 42 min read$CRL

Charles River Laboratories Announces Third-Quarter 2026 Results

Charles River Laboratories reported Q3 2026 revenue of $982.7M, GAAP EPS of $3.09, and non-GAAP EPS of $6.86, with organic revenue growth of 4.7%. The company raised its 2026 guidance, citing strong performance in the DSA segment and a lower tax rate. Operating margins improved year-over-year, and the company announced strategic initiatives to enhance operational excellence and scientific leadership.

Original reporting
stocktitan.net
Published Nov 4, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CRL
Bullish
high confidence
Mentioned
$CRL
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CRLBullishHigh
01

Why it matters

The earnings beat and guidance lift may attract momentum traders and long‑term investors focused on biotech services.

02

Market read

Strong quarterly performance and raised guidance suggest near‑term upside for CRL and related CRO stocks.

03

What to watch

Potential headwinds from regulatory changes or slower biotech pipelines could limit upside.

Relevance 8/10Novelty 8/10Timing: after release today

Background

Charles River Laboratories is a leading CRO providing preclinical and clinical testing services to pharma and biotech firms.

Company-level read

Ticker impact

$CRLBullishHigh confidence
Context

Charles River Laboratories reported Q3 2026 results with revenue beat and raised full-year guidance.

Expected impact

upward pressure as investors price in stronger demand and higher guidance

Evidence & confidence

Revenue and non‑GAAP EPS beat expectations; guidance raised on better DSA performance and lower tax rate.

Market effects

Sector

Boosts outlook for the contract research organization (CRO) sector.

Regional

Supports US biotech and pharma service stocks.

Global

Limited to life‑science services; no broad market effect.

Counterpoint

What could challenge this read

If guidance raise is driven mainly by tax benefits, earnings may not be sustainable.

Key entities

  • Company
    Charles River Laboratories

    US‑listed CRO reporting Q3 2026 results.

Read at source← All news

StoryCharles River Laboratories reports Q3 2026 earnings beat and raises 2026 outlook

Also covered by

5 outlets

Related articles

NOV 4
$CRLMedAI 8/10

Charles River Q3 2026 slides: organic growth returns but stock falls

Charles River Laboratories (CRL) reported Q3 2026 results with 4.7% organic revenue growth and non-GAAP EPS of $3.09, beating estimates. Despite this, shares fell 5.88% due to concerns over margin sustainability and delayed pricing power recovery. Revenue was $982.7M, with non-GAAP operating margin expanding to 23.0%. The DSA segment saw 5.9% organic growth, while Manufacturing grew 7.4% organically. Management expects pricing benefits to materialize in late 2027.

investing.com6 min
NOV 4
$CRLMedAI 8/10

Charles River Laboratories 2026: Revenue $982.73M, EPS $6.86— 10-Q Summary

Charles River Laboratories reported Q3 2026 revenue of $982.73M, down 2.2% YoY, while net income rose to $333.07M and EPS increased to $6.86. Management cited improving demand in Discovery and Safety Assessment, portfolio changes, and cost savings. Nine-month revenue declined 1.3%, with growth in microbial testing and China model sales. The company completed divestitures and acquisitions, targeting $300M in annual savings by 2026.

tradingview.com1 min
NOV 4
$CRLMed

Charles River Laboratories Lifts Annual Outlook- Update

Charles River Laboratories (CRL) raised its 2026 outlook, expecting revenue to decline 1.5%-2.0% (previously 2.5%-3.5%) and organic revenue to grow at least 1.5% (previously 0%-1%). EPS estimates increased to $8.15-$8.35 from $3.05-$3.35, with non-GAAP EPS at $11.35-$11.55. Q3 profit rose to $333.07M ($6.86/share) due to a $245.6M tax benefit, while revenue fell 2.1% to $982.732M. Shares dropped nearly 4% in pre-market trading.

rttnews.com2 min
NOV 4
$CRLHighAI 8/10

Charles River: Q3 Earnings Snapshot

Charles River Laboratories (CRL) reported Q3 net income of $333.1M, or $6.86 per share. Adjusted earnings were $3.09 per share, exceeding analyst estimates of $2.98 per share. Revenue was $982.7M, surpassing expectations of $956.8M. The company expects full-year earnings between $11.35 and $11.55 per share.

finance.yahoo.com2 min